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Abstract: Histone lysine demethylases (KDMs) are of critical
importance in the epigenetic regulation of gene expression, yet
there are few selective, cell-permeable inhibitors or suitable
tool compounds for these enzymes. We describe the discovery
of a new class of inhibitor that is highly potent towards the
histone lysine demethylases KDM2A/7A. A modular synthetic
approach was used to explore the chemical space and accel-
erate the investigation of key structure–activity relationships,
leading to the development of a small molecule with around 75-
fold selectivity towards KDM2A/7A versus other KDMs, as
well as cellular activity at low micromolar concentrations.
Chemical modifications of DNA and its associated histones
regulate gene expression across the entire genome, and
therefore have a profound impact on a number of fundamen-
tal biological processes.[1] As a result, targeting the epigenetic
pathways responsible for these chemical modifications may
represent a pivotal approach to addressing disease at the
transcription level.[2] In order to realize the potential of
epigenetics in drug discovery, a toolkit of chemical probes
that selectively target individual epigenetic proteins and allow
researchers to clearly identify their downstream effects is
invaluable.[3] Significant progress has been made towards the
development of a library of chemical probes that target the
proteins involved in histone acetylation, in particular the
bromodomain family of epigenetic readers.[4] In contrast,
proteins involved in the dynamic methylation of histone
lysine residues have proven to be more challenging targets,
especially the histone lysine demethylases (KDMs).[5]
The majority of KDMs belong to the Jumonji C (JmjC)
family of enzymes, which contain a catalytically-active FeII ion
in the active site and require a 2-oxoglutarate (2-OG)
cofactor for demethylation in the catalytic JmjC domain.[6]
The JmjC KDMs may be divided into six sub-families
(KDM2–KDM7) based on substrate specificity, with KDM2
and KDM7 being closely related.[7] A major challenge in
generating chemical probes for KDMs is achieving selectivity
between these structurally similar sub-families. Currently,
most inhibitors of the JmjC KDMs are iron-chelating 2-OG
competitors (Figure 1).[8–14] Although many of these mole-
cules achieve high levels of in vitro potency, they are
frequently limited by a lack of selectivity and activity in
cells. Peptide inhibitors that either mimic the histone
Figure 1. Previously discovered KDM2/7 inhibitors, and this work.
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substrate or bind KDMs allosterically have also been
reported,[15] however peptides are often limited by their low
cellular permeability. Herein, we describe the discovery of
a first-in-class, cell-permeable KDM2A/7A inhibitor that
exhibits more than or equal to 75-fold selectivity relative to
other JmjC KDM sub-families.
KDM2A catalyses the demethylation of mono- and
dimethylated lysine 36 on histone H3 (H3K36).[16] The
enzyme has been reported to be involved in the regulation
of NF-kB signalling[17] and the control of stem-cell differ-
entiation and proliferation.[18] Its overexpression in gastric
and small-cell lung cancer cells suggests that inhibiting
KDM2A may represent a strategy for targeting certain
cancers at the transcription level.[19,20] All KDM2A inhibitors
described to date are 2-OG competitors, and none are truly
selective. In addition, many 2-OG competitors show reduced
activity in cells, mainly due to poor cellular permeability and
the high intracellular concentration of 2-OG.[21] We therefore
envisioned an inhibitor that would mimic the structure of the
histone substrate rather than the 2-OG co-substrate, as
postulated for the KDM7A inhibitor E67-2.[22]
To identify a starting point, a library of known binders to
methyllysine reader domains and histone methyl transferases
was screened for inhibitory activity against a panel of KDMs,
since we reasoned that such a specialized library would be
more likely to contain molecules that also interact with
demethylases. Compound 1, which was prepared as a putative
methyllysine binding domain inhibitor,[23] was identified as
a promising candidate for further optimization against
KDM2A. However, attempts to significantly improve
potency by functionalizing at the indole NH position and
varying the aromatic substituent on the indole C-2 position
were unsuccessful. The pyrrolidine moiety in compound 1 was
shown to be critical for potency, which we postulated was due
to its role as a H3K36me2 mimic. Preliminary docking studies
of 1 with KDM2A (PDB ID: 2YU1; Figure S11 and Sec-
tion S8 in the Supporting Information) indicated a potential
for occupancy of the peptide binding site on the enzyme.
Based on this initial model, we subsequently hypothesized
that inhibitory activity towards KDM2A might be improved
by replacing the original indole scaffold with a saturated
indoline ring system. We envisioned an exploration of three-
dimensional chemical space around this core, with the aim of
augmenting selectivity through increasing complexity.[24] To
achieve this, a modular synthetic approach was employed to
generate a library of indoline-containing compounds and
identify key structure–activity relationships (Scheme 1A).
A base-mediated 5-endo-trig cyclization of a C-2-substi-
tuted aromatic imine afforded the racemic indoline core with
two adjacent stereocenters. Subsequent acylation of the
indoline ring system conferred stability towards oxidation
and provided a handle for modulating polarity. Finally, metal-
catalysed cross-coupling of the aryl bromide provided access
to a variety of linkers between the indoline core and
pyrrolidine capping group. In total, 45 racemic compounds
were synthesized, and IC50 values for inhibition of KDM2A
were determined using two orthogonal enzyme activity
assays: AlphaScreen[25] and RapidFireMS[26] (see Section S3.1
in the Supporting Information for complete inhibition data).
Key structure–activity relationships are summarized below
(Scheme 1B, compounds 2–12). We examined different link-
ers and found that triazole (2), ether (3), and alkyne (4)
linkers were well tolerated, with significantly lower IC50
values than the original hit. Reduction of the alkyne func-
tional group in 4 to an alkene (5) or an alkane (6) also
improved potency. Molecules containing a pyridine ring at the
indoline C-2 position were marginally more active than
analogues bearing other aromatic groups such as furan (7 or
8) and significantly more active than a substituted benzene
(9). In addition, pyridine-containing compounds displayed the
highest selectivity towards KDM2A (Section S3.1). Explora-
tion of substituents at the all-carbon quaternary stereocenter
as in 10 and 11 demonstrated that a Ph,CN combination gave
rise to the most potent series of compounds. Unfortunately,
12, the most potent inhibitor identified, was found to be
reactive in aqueous solution due to the susceptibility of the a-
aminoacetyl group to hydrolysis. However, the N-acetyl
group present in compounds 2–10 proved inert to hydrolytic
cleavage. The optimal length of the linker connecting the
indoline core to the pyrrolidine capping group was found to
be 7–8 atoms, and replacing pyrrolidine with other secondary
amines or a cyclopentyl ring led to a significant drop in
potency (Section S3.1).
Having succeeded in augmenting the potency of our initial
hit compound, we focused on the development of enantiose-
lective syntheses of 3 and 6 using a counterion-mediated
strategy (Scheme 1C).[27] Cyclization of imine 13 with
CsOH·H2O in the presence of quinine-derived salt 14
afforded (S,S)-15 as the major product (10:1 d.r.) with 88:12
e.r. The OBn substituent on the pyridine ring was found to be
crucial for attaining good levels of stereoselectivity. Pseudoe-
nantiomeric ammonium salt 16 afforded (R,R)-15 as the
major product (7:1 d.r.) with acceptable e.r. (17:83). Enantio-
purity was subsequently augmented (to > 99:1 e.r.) by
preparative HPLC. N-Acetylation and hydrogenolysis of the
benzyl group afforded common intermediate 17, which could
be converted into (S,S)- and (R,R)-3 through alkylation with
1,7-dibromoheptane and subsequent treatment with pyrroli-
dine. Alternatively, (S,S)- and (R,R)-6 could be synthesized
through O-triflation, Sonogashira coupling (with 1-(6-
heptyn)-pyrrolidine), and reduction of the resulting alkyne.
The (S,S) enantiomers of 3 and 6 were found to be slightly
more potent than their respective (R,R) analogues, and (S,S)-
6 (IC50 : 0.16 mm) was assessed further in a variety of biological
assays. In immunofluorescence assays using HeLa cells
ectopically expressing catalytically active KDM2A, a dose-
dependent increase in H3K36me2 staining was observed upon
incubation with (S,S)-6, reflecting augmented cellular
H3K36me2 levels (Figure 2A and Section S3.3). No signifi-
cant change in H3K36me2 fluorescence was observed for
cells containing constitutively inactive KDM2A (Sec-
tion S3.3).[28] Cytotoxicity towards HeLa and HAP1 cells
was observed at higher concentrations (EC50 22 mm and 7.1 mm
respectively), and (S,S)-6 showed a similar effect on the
viability of human fibroblasts (HDFa; EC50 : 10 mm) to GSK-
J4, a well-characterized chemical probe for KDM5/6[9]
(Section S3.4). This suggests a potential activity window for
investigating the effects of KDM2A inhibition within cells. To
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profile its selectivity, (S,S)-6 was tested for inhibitory activity
against a panel of KDMs, methyllysine binding motifs, and
epigenetic enzymes. It was found to be remarkably selective
towards KDM2A (+ 100-fold) relative to representatives of
the other KDM sub-families, except closely related KDM7A
(H3K9/K27me2/me1 demethylase),[29] where it was similarly
potent (Figure 2B).[30] (S,S)-6 was inactive towards a repre-
sentative panel of methyllysine binding domains, methyl
transferases, and histone acetyl transferases (Section S3.2). To
our knowledge, this is the first time a KDM2A/7A-selective
small molecule has been shown to inhibit demethylation in
cells, with a significant reduction in demethylation achievable
at low mm concentrations. To explore its cellular activity
further, the effect of (S,S)-6 on gene expression in HAP1 cells
was monitored using a highly multiplexed 3’ mRNA sequenc-
ing method.[31] Within a diverse panel of in-house compounds,
our series of indoline-containing inhibitors was represented
by (S,S)-6 and the less active close analogue 18 (IC50 : 17 mm,
Figure 2C).
When dosed at a concentration of 10 mm, both molecules
influenced the expression levels of more than 200 genes.
However, at a concentration of 1 mm, only the active analogue
(S,S)-6 had a significant effect on expression levels (Fig-
ure 2D and Section S4). We postulate that this concentration
dependence is a consequence of predominantly off-target
effects at high concentrations, as opposed to a more specific
Scheme 1. A) General synthetic strategy for racemic synthesis of KDM2A inhibitors. Reagents and conditions: i) Zn powder (10 equiv), NH4Cl
(15 equiv), 5:1 acetone/H2O or H2, Pd/C (10% w/w), EtOAc; ii) ArCHO (1.3 equiv), MgSO4 (5 equiv), PhMe or ArCHO (1.3 equiv), pyrrolidine
(0.1 equiv), 3 b sieves, CH2Cl2 ; iii) KO
tBu (1.1 equiv), PhMe, 0 8C; iv) R3COCl (2–5 equiv), pyridine (2–5 equiv), CH2Cl2 ; v) metal-catalysed cross-
coupling. B) Key structure–activity relationships. IC50 values were determined by RapidFire MS and confirmed by AlphaScreen. All compounds are
racemic. C) Catalytic enantioselective synthesis. Reagents and conditions: i) CsOH·H2O (2.0 equiv), catalyst 14/16 (10 mol%), PhMe, @30 8C.
Catalyst 14 : 89%, d.r. 10:1, e.r. 88:12; catalyst 16 : 84%, d.r. 7:1, e.r. 17:83; ii) CH3COCl (2.0 equiv), pyridine (2.0 equiv), CH2Cl2 ; iii) H2, Pd/C
(10% w/w), 88% (2 steps); iv) K2CO3 (5 equiv), Br(CH2)7Br (4 equiv), acetone, reflux, 38%; v) K2CO3 (5 equiv) pyrrolidine (4 equiv), CH3CN, 65%;
vi) PhN(SO2CF3)2 (1.1 equiv), DIPEA (2.0 equiv), CH2Cl2, 0 8C, 85%; vii) 7-pyrrolidine-hept-1-yne (1.5 equiv), PdCl2(PPh3)2 (5 mol%), CuI (5 mol%),
HN(iPr)2, 75 8C, 79%; viii) H2, Pd/C (10% w/w), MeOH, 74%. DIPEA= (
iPr)2NEt.
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effect resulting from KDM2A/7A inhibition at low concen-
trations. The overlap of the gene expression signatures of
(S,S)-6 and 18 is depicted in Figure 2E.
Obtaining a co-crystal structure of (S,S)-6 bound to
KDM2A proved challenging, and hence, non-denaturing
mass spectrometry (MS) experiments were performed to
determine the binding stoichiometry of (S,S)-6 to KDM2A.
KDM2A was incubated with (S,S)-6 and subsequently intro-
duced into a mass spectrometer under conditions optimized
for the preservation of noncovalent interactions.[32] The native
mass spectrum (Figure 3) shows 1:1 binding of (S,S)-6 to
KDM2A. To verify the identity of bound (S,S)-6, we
performed tandem-MS on the 14+ charge state, resulting in
the removal of (S,S)-6 as a singly charged species (Figure 3C,
see inset).
Kinetic analyses subsequently revealed that (S,S)-6 does
not display competitive inhibition kinetics with respect to
either 2-OG or the peptide substrate (Section S6), thus
suggesting a different mode of inhibition to the majority of
previously discovered KDM inhibitors.[33] Consistent with this
observation, (S,S)-6 did not displace fluorescent methylstat (a
“bivalent” substrate-cofactor tracer for KDM2A) in fluores-
cence polarisation assays. To probe the (S,S)-6 binding site
further, KDM2A was subjected to a photoaffinity labelling
profile with a diazirine-containing analogue of (S,S)-6, and
LC-MS/MS experiments were conducted (Section S7). The
majority of covalently modified residues were found to be
either aspartic or glutamic acids, thus suggesting the forma-
tion of a relatively long-lived electrophilic intermediate
following photo-induced isomerization of the diazirine to
a diazo compound.[34] While this precludes the unambiguous
determination of the inhibitor binding site, the observed lack
of labelling within the JmjC domain active site (Section S7) is
consistent with the observed lack of competitive inhibition
with respect to either 2-OG or the peptide substrate. This may
indicate the presence of an alternative (allosteric) binding site
specific to KDM2A/7A, although further investigation is
necessary to demonstrate this clearly.
In conclusion, we have developed a potent and selective
first-in-class inhibitor of the histone lysine demethylases
KDM2A/7A. Compound (S,S)-6 displays more than 75 fold
selectivity towards KDM2A/7A versus other JmjC lysine
demethylases and is, to our knowledge, the first reported
selective KDM2A/7A inhibitor that has been demonstrated
to reduce H3K36me2 demethylation within cells. This study
demonstrates how the generation of three-dimensional scaf-
folds bearing significant saturation and multiple chiral centres
can lead to the discovery of selective compounds that may be
useful in the study of a challenging epigenetic target.
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